haematology
Gail Model for Breast Cancer Risk
5-year and lifetime absolute risk of invasive breast cancer. Based on the NCI Breast Cancer Risk Assessment Tool (BCRAT). Used to identify women who may benefit from chemoprevention (tamoxifen, raloxifene, aromatase inhibitors).
References
- Gail MH et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
- NICE NG12. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. NICE. 2013 (updated 2019).
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Tamoxifen · Selective oestrogen receptor modulator (SERM)
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.